ClinicalTrials.gg
Status unknownNCT04926363NEVRITEUpdated Oct 7, 2021

Prevalence of Cardiovascular Risk Factors in Upper Vestibular Neuritis

An observational study in Vestibular Neuritis, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-07.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

Vestibular neuritis is the second cause of vertigo, it constitutes 5 to 6% of the aetiologies of vertigo in an otoneurological consultation.

Infection or reactivation of a neurotropic virus of the herpes group (HSV-1) in the vestibular lymph node is thought to be the cause of the unilateral vestibular deficit.

Upper vestibular neuritis is more common than lower, or total involvement. Goebel (2) explains this by an anatomical predisposition of the vestibular nerve canal to inflammation, unlike the singular nerve canal which is shorter and wider giving way to a certain degree of edema without consequence on its contents.

However, the innervation territory of the superior vestibular nerve is superimposable on the territory supplied by the anterior vestibular artery. The anterior, lateral semicircular canals and the utricle are affected. Current complementary vestibular and imaging examinations cannot differentiate between inflammatory or vascular involvement in upper vestibular neuritis.

The increased presence of cardiovascular risk factors in patients with upper vestibular neuritis would be an argument in favor of ischemic involvement of the anterior vestibular artery.

02

Conditions studied

  • Vestibular Neuritis

Browse trials for

Keywords

  • Vestibular neuritis
  • Anterior vestibular artery
03

In context

Vestibular Neuronitis

34 studies on the registry are indexed under Vestibular Neuronitis; 4 are open to participants now.

Browse Vestibular Neuronitis studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Major having presented an episode of upper vestibular neuritis recorded on the Video Head Impulse Test Ulmer device at the HUS between 01/01/2016 and 01/31/2020,

Eligibility criteria

nclusion criteria:

  • Major subject (≥18 years old),
  • Subject having presented an episode of upper vestibular neuritis recorded on the Video Head Impulse Test Ulmer device at the HUS between 01/01/2016 and 01/31/2020,
  • Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research.

Exclusion criteria:

  • Patient who expressed his opposition to participating in the study,
  • Total vestibular neuritis,
  • impossibility of providing the subject with enlightened information (difficulties in understanding the subject, etc.)
  • Subject under safeguard of justice,
  • Subject under guardianship or guardianship,
  • Lack of video head impulse test data.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Retrospective study of cardiovascular risk factors in people with upper vestibular neuritis

    Time frame: Files analysed retrospectively from January 01, 2016 to January 31, 2020 will be examined]

07

Study locations

1 of 1 sites recruiting
  • Service ORL et de CCF - Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67091, France
    Recruiting
    • Anne CHARPIOT, MD, PhD · Contactanne.charpiot@chru-strasbourg.fr · 33 3 88 12 76 41
    • Saïd CHAYER, PhD, HDR · Contactsaid.chayer@chru-strasbourg.fr · 33 3 88 11 66 90
    • Anne CHARPIOT, MD, PhD · Principal investigator
    • Pauline Pâris, MD · Sub investigator
    • Idir Djennaoui, MD · Sub investigator
    • Francis Veillon, MD, PhD · Sub investigator
    • Pierre Mahoudeau, MD · Sub investigator
    • Pierre Etourneau, MD · Sub investigator
    • Julien GODET, Engineer · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04926363
Responsible party
Sponsor
First posted
Jun 15, 2021
Start date
Feb 1, 2020
Primary completion
Feb 1, 2022 (estimated)
Completion
Feb 4, 2022 (estimated)
Last update
Oct 7, 2021

Study contacts

Anne CHARPIOT, MD, PhD
Contact
anne.charpiot@chru-strasbourg.fr
33 3 88 12 76 41
Saïd CHAYER, PhD, HDR
Contact
said.chayer@chru-strasbourg.fr
33 3 88 11 66 90
Anne CHARPIOT, MD, PhD
study director · Service ORL et de CCF- Hôpitaux Universitaires de Strasbourg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion